A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia

Leukemia

Volumn 29, Issue 7, 2015, Pages 1478-1484

  Russell, N H ^a   Kjeldsen, L ^b   Craddock, C ^c   Pagliuca, A ^d   Yin, J A ^e   Clark, R E ^f   Howman, A ^g   Hills, R K ^h   Burnett, A K ^h  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b Rigshospitalet   (Denmark)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d KING S COLLEGE HOSPITAL   (United Kingdom)

^e MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^f ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^g UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^h CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MELPHALAN; MITOXANTRONE; ANTINEOPLASTIC AGENT;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ALLOGRAFT; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOGENETICS; FEMALE; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REDUCED INTENSITY CONDITIONING; SIBLING; ALLOTRANSPLANTATION; CANCER STAGING; FOLLOW UP; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; UNRELATED DONORS;

ADULT; ALLOGRAFTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SIBLINGS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS;

EID: 84936999939     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.319     Document Type: Article

References (17)

1. Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011; 29: 369-377
2. Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012; 379: 1508-1516
3. Burnett AK, Russell NH, Hills RK, Kell J, Freeman S, Kjeldsen L. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol. 2012; 30: 3924-3931
4. Cornelissen J, van Putten WLJ, Verdonck LF, Theobald M, Jacky E, Daenen SM, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLAidentical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-Aged adults: benefits for whom?. Blood. 2007; 109: 3658-3666
5. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-Analysis of prospective clinical trials. JAMA. 2009; 301: 2349-2361
6. Walter RB, Pagel JM, Gooley TA, Petersdorf EW, Sorror ML, Woolfrey AE, et al. Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. Leukemia. 2010; 24: 1276-1282
7. Burnett AK, Hills RK, Milligan DW, Goldstone AH, Prentice AG, McMullin MF, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol. 2010; 28: 586-595
8. Schlenk RF, Dohner K, Mack S, Stoppel M, Király F, Götze K, et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian Trial AMLHD98A. J Clin Oncol. 2010; 28: 4642-4648
9. Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O, et al. Graft-versus host disease following allogeneic transplantation from HLA-identical siblings with antithymocyte globulin-based reducedintensity preparative regimen. Blood. 2003; 102: 470-476
10. Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Shizuru JA, Greinix H, et al. Treatment for acute myelogenous leukemia by lowdose, total-body irradiationbased conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol. 2006; 24: 444-453
11. Mohty M, de Lavallade H, El-Cheikh J, Ladaique P, Faucher C, Fürst S, et al. Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a "donor" versus "no donor" comparison. Leukemia. 2009; 23: 194-196
12. Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013; 31: 3360-3368
13. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML: 10 Trial. Blood. 1998; 92: 2322-2333
14. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the international Working Group for diagnosis, standardization of response criteria treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003; 21: 4642-4649
15. Mantel N, Byar DP. Evaluation of response-Time data involving transient states: An illustration using heart-Transplant data. J Am Stat Assoc. 1974; 69: 81-86
16. McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010; 28: 1878-1887
17. Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood. 2004; 104: 961